- Home
- LPG vs GHRS Comparison
LPG vs GHRS Comparison
Compare LPG & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LPG | GHRS |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.8B |
| IPO Year | 2014 | 2021 |
Fundamental Metrics
Financial Performance| Metric | LPG | GHRS |
|---|---|---|
| Price | $47.37 | $29.49 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | $39.33 | ★ $41.38 |
| AVG Volume (30 Days) | ★ 593.4K | 388.6K |
| Earning Date | 05-21-2026 | 05-01-2026 |
| Dividend Yield | ★ 8.26% | N/A |
| EPS Growth | ★ 112.15 | N/A |
| EPS | ★ 3.24 | N/A |
| Revenue | ★ $481,511,242.00 | N/A |
| Revenue This Year | $35.73 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $14.08 | ★ N/A |
| Revenue Growth | ★ 36.27 | N/A |
| 52 Week Low | $23.76 | $11.83 |
| 52 Week High | $48.12 | $31.44 |
Technical Indicators
Market Signals| Indicator | LPG | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 60.45 | 58.21 |
| Support Level | $39.82 | $13.06 |
| Resistance Level | $48.00 | $31.22 |
| Average True Range (ATR) | 1.96 | 1.49 |
| MACD | -0.02 | -0.09 |
| Stochastic Oscillator | 86.17 | 71.35 |
Price Performance
Historical ComparisonAbout LPG Dorian LPG Ltd.
Dorian LPG Ltd is an international liquefied petroleum gas shipping company focused on owning and operating gas carriers, or VLGCs. The company currently owns and operates around 22 modern VLGCs, including nineteen new fuel-efficient 84,000 cbm ECO-design VLGCs. Dorian LPG has offices in Connecticut, USA, London, United Kingdom, and Athens, Greece. IT operates in one reportable segment, the international transportation of LPG.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.